Form 4 for PMVP PMV Pharmaceuticals, Inc.
Accepted 2022-04-29 00:00:00 ET · period of report 2022-04-27 · accession 0001209191-22-026341 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-29 | 2022-04-27 | PMVP | Mack David Henry | Pres, CEO, Dir | M - OptEx | $0.53 | +33.0K | 80.0K | +70% | +$17.5K |
| D | 2022-04-29 | 2022-04-27 | PMVP | Mack David Henry | Pres, CEO, Dir | M - OptEx | $0.00 | -33.0K | 393.4K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-27 | M | A | 33,000 | $0.53 | 79,970 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-04-27 | M | D | 33,000 | $0.00 | 393,366 | D | $0.53 · — to 2025-05-11 | 33,000 Common Stock | (F5) Due to an administrative error, the Form 4 filed on May 24, 2021 overstated the number of derivative securities beneficially owned following the reported transaction by 6,207 shares and has been updated in this Form 4 to correct the error. (F4) The shares subject to the option are fully vested and immediately exercisable. |